Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.

BACKGROUND: Drug response variability observed amongst patients is caused by the interaction of both genetic and non-genetic factors, and frequencies of functional genetic variants are known to vary amongst populations. Pharmacogenomic research has the potential to help with individualized treatments. We have not found any pharmacogenomics information regarding Uygur ethnic group in northwest China. In the present study, we genotyped 85 very important pharmacogenetic (VIP) variants (selected from the PharmGKB database) in the Uygur population and compared our data with other eleven populations from the HapMap data set. RESULTS: Through statistical analysis, we found that CYP3A5 rs776746, VKORC1 rs9934438, and VKORC1 rs7294 were most different in Uygur compared with most of the eleven populations from the HapMap data set. Compared with East Asia populations, allele A of rs776746 is less frequent and allele A of rs7294 is more frequent in the Uygur population. The analysis of F-statistics (Fst) and population structure shows that the genetic background of Uygur is relatively close to that of MEX. CONCLUSIONS: Our results show significant differences amongst Chinese populations that will help clinicians triage patients for better individualized treatments.

Clinical observation of external irradiation combined with 252Cf brachytherapy on advanced cardiac carcinoma / 肿瘤研究与临床

Objective To observe the efficacy and the toxicity of external irradiation combined with 252Cf brachytherapy on advanced cardiac carcinoma.Methods 48 patients with advanced cardiac carcinoma hospitalized during March 2007 to December 2010 were recruited,in which 39 cases were adenocarcinoma,5 patients were squamous carcinoma and 4 cases were signet-ring cell carcinoma.All cases had a Kamofsky above 80,no metastasis and received radiotherapy sequenced external and internal irradiation.The external irradiation was conducted under a 6MV X linear accelerator,and a dose of 38-45 Gy (2 Gy/22 f).The type ZH-1000 252Cf neutron breach-loading machine was used for brachytherapy with a dose of 12-16 Gy.Results Dysphagia cleared in all cases.The short-term efficacy (PR+CR) rate was 91.7 ％ (44/48).One and two year survival rate were,respectively,39.6 ％ and 6.3 ％.25 (52.1％) patients had gastrointestinal symptoms such as nausea,vomiting and impedance,and grade 1,2 neutropenia were occurred in 21 (43.8 ％) and 3 (6.3 ％) patients.Conclusion External irradiation combined with 252Cf brachytherapy is a safe,effective and tolerable treatment for advanced cardiac carcinoma.